Lux Biosciences (Jersey City, NJ) a clinical-stage biotechnology company focused on ophthalmic diseases, closed a $50M Series B financing. Participants include HBM Bioventures, De Novo Ventures, Prospect Venture Partners, SV Life Sciences and International Biotechnology Trust.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Tarsa Therapeutics (Boonton, NJ) a clinical stage small molecule company focused on osteoporosis closed a $24M Series A financing. Participants include MVM Life Science Partners, Quaker BioVentures and Novo Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

DNP Green Technology (Princeton, NJ) a development-stage bioagriculture company focused on processes for making bio-derived succinic acid and its derivatives for the production of chemicals and polymers, closed a $12M Series A financing. Participants include Sofinnova Partners, Mitsu Ventures, Samsung Ventures Investment Corporation, Cliffton Group, AquaRIMCO, Touradji Capital Management, Toyota Tsusho Corporation and Japan Asia [...]

VaxInnate (Cranbury, NJ) a clinical-stage vaccine company focused on infectious disease including flu, malaria, dengue, papillomavirus, and respiratory syncytial virus, closed a $30M Series D financing. Participants include Wellcome Trust, New Leaf Venture Partners, Canaan Partners, HealthCare Ventures, Oxford Bioscience Partners, MedImmune Ventures and CHL Medical Partners.

Orthocon (North Brunswick, NJ) a preclinical-stage company focused on implantable devices that deliver therapeutics to bone, closed a $25M Series B financing. Participants include ProQuest Investments, Canaan Partners and BB Biotech Ventures.

CircuLite (Saddle Brook, NJ) a clinical-stage company focused on a cardiovascular device for the treatment of heart failure via minimally-invasive micro-pumps for long-term partial circulatory support , closed a $23.5M Series C financing. Participants include Forbion Capital Partners, Crédit Agricole Private Equity, Foundation Medical Partners and Oxford Bioscience Partners.

Sopherion Therapeutics (Princeton, NJ) a late-stage oncology company with European and Canadian as a first-line therapy in combination with cyclophosphamide for patients with metastatic breast cancer, closed a $55M Series C financing. Participants include Zoticon BioVentures, Sprout Group, ProQuest, Canaan Partners, HealthCap, NewSpring Ventures, Commerce Health Ventures and Seaflower Ventures.

InSet Technologies (Mt. Olive, NJ) an early-stage company developing implantable pumps delivering targeted medications directly to the spinal cord (intrathecal space) to achieve potentially improved functional relief with a dramatic reduction in the side effects from high doses of drugs for chronic pain, closed a $25M Series B financing. Participants include Clarus Ventures and [...]

Chiral Quest (Monmouth Junction, NJ) a CMO specializing in production of complex API’s, closed a $13M Series B financing. Participants include Infinity I-China, Kleiner Perkins Caufield & Byers, the China Spring Fund and JAIC.